Renova Therapeutics

27 articles about Renova Therapeutics

• Renova Therapeutics Announces Issuance of Patent Covering Delivery and Expression of Paracrine Genes

  3/27/2018

  Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the European Patent Office has issued Patent No. 2814513, "Systemic Delivery and Regulated Expression of Paracrine Genes for Cardiovascular Diseases and Other Conditions" to The Regents of the University of California

• Renova Therapeutics to Present Key Components of FLOURISH Gene Therapy Trial for the Treatment of Heart Failure at Keystone Symposium

  1/12/2018

  Renova announced today that it will present an overview of its RT-100 AC6 gene transfer Phase 3 clinical trial in a poster session at the Keystone Symposium on Heart Failure on January 14-18, 2018, in Keystone, Colorado.

• FDA Grants Fast Track Designation to Renova Therapeutics' RT-100 AC6 Gene Transfer for the Treatment of Heart Failure

  12/14/2017

  RT-100 AC6 gene transfer involves infusing an inactivated adenovirus vector encoding human adenylyl cyclase type 6 into the arteries that feed the heart during cardiac catheterization, a commonly performed procedure.

• Renova Therapeutics Release: PLOS ONE Publishes Results Of Cardiac-Directed Catalytically Inactive AC6 In Mice After Sustained ß-Adrenergic Stimulation

  8/3/2017

• Renova Therapeutics Release: Urocortin 2 Gene Transfer Increases Glucose Disposal And Insulin Sensitivity In Type 2 Diabetes

  7/18/2017

• Industry Leaders Join Renova Therapeutics To Lead Preclinical Programs Into Clinical Development

  5/2/2017

• Renova Therapeutics Release: Human Gene Therapy Publishes Review Of Randomized Clinical Trials Of Gene Transfer For Heart Failure With Reduced Ejection Fraction

  4/11/2017

• Renova Therapeutics Release: U.S. Patent For Urocortin 2 Gene Constructs Issued

  2/21/2017

• Renova Therapeutics Enters Into Agreement To Receive Stresscopin Investigational New Drug File From Janssen Pharmaceutical

  2/6/2017

• Renova Therapeutics Selects Worldwide Clinical Trials As Its Clinical Research Organization For Phase 3 Trial Of RT-100 AC6 Gene Transfer

  1/6/2017

• Renova Therapeutics Secures Novel AAV Vector License For Use In Metabolic And Cardiovascular Gene Therapy Development

  12/8/2016

• Biotech Finance Expert Joins Renova Therapeutics As CFO

  12/5/2016

• Renova Therapeutics Announces Successful End-Of-Phase 2 Meeting With FDA For RT-100 AC6 Gene Transfer Therapy

  11/1/2016

• Renova Therapeutics Strengthens Gene Therapy IP Estate With Latest Patent License

  10/11/2016

• Renova Therapeutics To Present On Advancing Gene Therapy For Chronic Diseases At 18th Annual Biojapan Conference

  10/6/2016

• Renova Therapeutics Release: The Journal Of Clinical Investigation Insight Publishes Preclinical Results Of Urocortin 2 Gene Transfer In Mouse Models Of Insulin Resistance

  9/22/2016

• Development-Stage Biotech Renova Therapeutics Partners With NASDAQ Private Market

  9/12/2016

• Renova Therapeutics Selected To Present At Cavendish Global Health Impact Forum At BIOCOM

  6/15/2016

• Renova Therapeutics Expands Clinical Development Team With Latest Hire

  6/1/2016

• Renova Therapeutics Release: The JAMA Cardiology Publishes Phase 2 Results Of AC6 Gene Transfer In Patients With Heart Failure

  3/30/2016